United States Drug Enforcement Administration

Thank you and good morning. Thank you to ONDCP and to all the federal partners with whom we have been working on this important issue. This is a critical moment in our country. DEA’s mission is to keep American communities safe and healthy and we are in the midst of...

WASHINGTON – With the unprecedented worldwide health emergency brought on by COVID-19, last year was filled with new challenges and increased risks. While much of the world focused on combating the pandemic, DEA continued to implement initiatives to combat violent drug traffickers who were intent on flooding cities and rural...

TULSA , Okla. – An Owasso physician pleaded guilty today in U.S. District Court to leading multiple conspiracies to write fraudulent opioid prescriptions in an effort to support his drug habit. Special Agent in Charge Clyde E. Shelley, Jr., of the U.S. Drug Enforcement Administration and United States Attorney Trent...

DALLAS – Special Agent in Charge of the U.S. Drug Enforcement Administration’s Dallas Division Clyde E. Shelley, Jr. announced that with the robust participation of Americans nationwide, DEA and its law enforcement partners have now surpassed its 10 million pound goal and collected nearly 11 million pounds of unused, unwanted...

DALLAS - Clyde E. Shelley, Jr. the Special Agent in Charge of the U.S. Drug Enforcement Administration’s Dallas Division announced that the DEA Dallas Field Division is partnering with national, state, local, and tribal law enforcement officials, as well as community coalition groups, during its 16th National Prescription Drug Take-Back...

WASHINGTON – The Drug Enforcement Administration today announced action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018. Published in today’s Federal Register, DEA’s action puts N-Ethylpentylone into Schedule I of the Controlled Substances Act. Schedule I substances refer to...

WASHINGTON – The Department of Justice and U.S. Drug Enforcement Administration have proposed a reduction for controlled substances that may be manufactured in the U.S. next year. Consistent with President Trump’s “Safe Prescribing Plan” that seeks to “cut nationwide opioid prescription fills by one-third within three years,” the proposal decreases...